On September 1, the 2026 edition of the “National Essential Medicines Catalogue” jointly issued by the three departments of the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Administration for Disease Control and Prevention was officially implemented. After a lapse of 8 years, the basic drug catalogue once again ushered in a major expansion. According to official sources, a total of 794 types of drugs have been included in the new catalogue, and 116 new types of drugs have been added, including 68 types of chemicals and biological products, and 48 types of proprietary Chinese medicines. Retrieve 2 types of chemicals and biological products from the original catalogue, and no proprietary Chinese drugs were transferred out. In addition to the expansion of conventional drugs, the most notable change in the new version of the basic drug catalogue “opens the door” to innovative drugs on a large scale. What is the most significant trend vane is that a total of 4 domestically produced Class 1 new drugs have been added to the catalogue, namely Xiansheng Pharmaceutical's edaravone dextrol, Rongchang Biotech's taitacip, Connoya's sipcibalizumab, and Eling Pharmaceutical's anti-depression and anti-stress capsules. In addition, Novo Nordisk's star GLP-1 hypoglycemic drug simeglutide also appeared on the new list.

On September 1, the 2026 edition of the “National Essential Medicines Catalogue” jointly issued by the three departments of the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Administration for Disease Control and Prevention was officially implemented. After a lapse of 8 years, the basic drug catalogue once again ushered in a major expansion. According to official sources, a total of 794 types of drugs have been included in the new catalogue, and 116 new types of drugs have been added, including 68 types of chemicals and biological products, and 48 types of proprietary Chinese medicines. Retrieve 2 types of chemicals and biological products from the original catalogue, and no proprietary Chinese drugs were transferred out. In addition to the expansion of conventional drugs, the most notable change in the new version of the basic drug catalogue “opens the door” to innovative drugs on a large scale. What is the most significant trend vane is that a total of 4 domestically produced Class 1 new drugs have been added to the catalogue, namely Xiansheng Pharmaceutical's edaravone dextrol, Rongchang Biotech's taitacip, Connoya's sipcibalizumab, and Eling Pharmaceutical's anti-depression and anti-stress capsules. In addition, Novo Nordisk's star GLP-1 hypoglycemic drug simeglutide also appeared on the new list.